KARRIE SWEET: Open Payments
NPI 1831488477 · PORTLAND, ME. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,277 in 29 payments from 10 companies in 2025. Trend: 2023 $1,325 · 2024 $1,151 · 2025 $1,277
Food & beverage: $1,277
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $365 |
| Madrigal Pharmaceuticals | 6 | $321 |
| GENZYME CORPORATION | 6 | $198 |
| Gilead Sciences, Inc. | 2 | $128 |
| Medtronic, Inc. | 1 | $94 |
| ORPHALAN INC | 2 | $58 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Ipsen Biopharmaceuticals, Inc | 1 | $31 |
| Lilly USA, LLC | 1 | $26 |
| Novo Nordisk Inc | 1 | $19 |
Products named: TREMFYA, REZDIFFRA, DUPIXENT, Livdelzi, INTERSTIM, CUVRIOR, IQIRVO, OMVOH.
Industry payments across ME — which companies pay providers there.
